Wistar Scientist Chosen For Lupus Foundation of Philadelphia's Sheryl N. Hirsch Award

June 10, 1998

Philadelphia -- Andrew Caton, Ph.D., an associate professor in The Wistar Institute's Tumor Immunology Program, has been chosen to receive the Lupus Foundation of Philadelphia's prestigious Sheryl N. Hirsch Award.

This year marks the third time Dr. Caton has received this award for his research on system lupus erythematosus, a complex disease thought to result from a faulty immune system. In particular, he is examining immune responses to foreign antigens. His findings are expected to provide insights into the role infections play in the initiation and exacerbation of lupus.

Dr. Caton came to The Wistar Institute in 1984, after earning his Ph.D. in virology from the University of Cambridge, U.K., and working as a postdoctoral assistant in molecular biology at the University of Oxford, U.K.

Sheryl N. Hirsch, for whom the annual award is named, died of lupus in 1981. She and her mother, Goldie Simon, founded the Lupus Foundation of Philadelphia to educate patients, their families, the medical community and the general public about lupus, and to promote research in the hope of finding a cure.
The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.

The Wistar Institute

Related Lupus Articles from Brightsurf:

Systemic lupus erythematosus (SLE)
If renal remission is achieved therapeutically in cases of lupus nephritis (LN), the 10-year survival rate increases significantly.

Race-specific lupus nephritis biomarkers
A University of Houston biomedical researcher has discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

Lupus patients who take their medications lower their diabetes risk
Patients with lupus who take their medications as prescribed have much lower odds of developing type 2 diabetes, a common complication of the disease, finds a new study from the University of British Columbia.

Nearly 1 in 3 patients with lupus use prescription opioids for pain
A new study finds nearly one in three adults with lupus use prescription opioids to manage pain, despite a lack of evidence that opioids are effective for reducing pain from rheumatic diseases.

Developing therapeutic strategies for pregnant women with lupus
A highly gender-biased disease, lupus afflicts females some nine times more than males.

Lupus antibody target identified
Researchers have identified a specific target of antibodies that are implicated in the neuropsychiatric symptoms of lupus, according to human research published in JNeurosci.

B cells off rails early in lupus
Emory scientists could discern that in people with SLE, signals driving expansion and activation are present at an earlier stage of B cell differentiation than previously appreciated.

Can adverse childhood experiences worsen lupus symptoms?
Adverse childhood experiences (ACEs) encompass traumas such as abuse, neglect, and household challenges.

Unlocking the female bias in lupus
The majority of lupus patients are female, and new findings from the University of Pennsylvania shed light on why.

How a single faulty gene can lead to lupus
IBS-AIM (Academy of Immunology and Microbiology) research team at Pohang University of Science and Technology (POSTECH) in South Korea has discovered the role of a key gene involved in the autoimmune disease systemic lupus erythematosus (SLE) or lupus for short.

Read More: Lupus News and Lupus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.